Koers Medivir AB (publ) OTC Markets
Aandelen
MVRBF
SE0020181014
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 32,3 mln. 3,02 mln. 2,78 mln. | Omzet 2025 * | 52,05 mln. 4,87 mln. 4,49 mln. | Marktkapitalisatie | 328 mln. 30,71 mln. 28,29 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -75 mln. -7,02 mln. -6,46 mln. | Nettowinst (verlies) 2025 * | -92 mln. -8,61 mln. -7,93 mln. | EV/omzet 2024 * | 5,06 x |
Nettoliquiditeiten 2024 * | 165 mln. 15,41 mln. 14,2 mln. | Nettoliquiditeiten 2025 * | 245 mln. 22,92 mln. 21,12 mln. | EV/omzet 2025 * | 1,6 x |
K/w-verhouding 2024 * |
-5,44
x | K/w-verhouding 2025 * |
-2,37
x | Werknemers | 10 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 64,1% |
Recentste transcriptie over Medivir AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jens Lindberg
CEO | Chief Executive Officer | 53 | 24-01-22 |
Director of Finance/CFO | 50 | 12-08-19 | |
Uli Alf Hacksell
CHM | Chairman | 74 | 03-05-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 03-05-18 |
Director/Board Member | 68 | 03-05-18 | |
Yilmaz Mahshid
BRD | Director/Board Member | 45 | 26-05-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,63% | 115 mld. | |
+13,17% | 107 mld. | |
-12,76% | 22,31 mld. | |
-3,99% | 21,6 mld. | |
-7,19% | 18,23 mld. | |
-39,93% | 17,62 mld. | |
+6,67% | 14,26 mld. | |
+33,90% | 12,37 mld. | |
-28,60% | 8,28 mld. |